Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives
Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives
复制标题
DOI：
10.1517/14712590802680158
复制
发表时间：
2009-03-01
影响因子：
6.1
通讯作者：
Del Prete, Salvatore
中科院分区：
文献类型：
--
作者：
Addeo, Raffaele;Caraglia, Michele;Del Prete, Salvatore
这次意大利会议由意大利南方肿瘤组（GOIM）共同主办，重点关注肝细胞癌（HCC）的不同方面。主题包括流行病学研究、环境和遗传风险因素的确定、发病机制的分子机制、新的诊断方法以及标准和新的治疗方式。HCC仍然是世界范围内的主要健康问题。它是世界上第五大最常见的癌症，也是第三大最常见的癌症相关死亡原因。肝癌管理的目标是“癌症控制”，降低其发病率和死亡率，并改善肝癌患者及其家人的生活质量。本文描述了坎帕尼亚地区肝癌的流行病学以及丙型肝炎病毒和B型肝炎病毒在肝癌发病机制中的作用。随后，对作为HCC治疗靶点的转导途径的最新技术水平和前景进行了评价。另一个会议是关于通过成像技术诊断HCC。最后一次会议是专门针对这种癌症的临床治疗，肝移植的作用，手术切除，局部区域程序和系统治疗方式。最后，给出了So.Lar.介绍了索拉非尼+奥曲肽长效释放（LAR）联合用药的研究。
This Italian meeting, co-sponsored by the Italian Southern Oncological Group (GOIM), focused on different aspects of hepatocellular carcinoma (HCC). Topics included epidemiological studies, identification of environmental and genetic risk factors, the molecular mechanisms of pathogenesis, new diagnostic approaches and standard and novel treatment modalities. HCC remains a major health problem worldwide. it is the fifth most common cancer in the world, and the third most common cause of cancer-related death. The goal of HCC management is 'cancer control', reduction in its incidence and mortality as well as improvement in the quality of life of patients with HCC and their families. HCC epidemiology in Campania and the role of hepatitis viruses C and B in the pathogenesis of this cancer were described. Subsequently, state of the art and perspectives on the transduction pathways as therapeutic targets in HCC were evaluated. Another session was about HCC diagnosis by imaging techniques. The last session was dedicated to clinical treatment of this cancer, the role of liver transplantation, surgical resection, loco-regional procedures and systemic treatment modalities. Finally, the final results of the So.Lar. study on the Sorafenib + octreotide long-acting release (LAR) combination were presented.